|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.72 CHF | -0.93% |
|
+0.52% | -6.01% |
| 11:24am | Carl Zeiss Meditec surges as cost-cutting measures take center stage | DP |
| 07:00am | UBS AG : Goldman Sachs remains Neutral | ZD |
Company Valuation: UBS Group AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 56,576 | 54,752 | 84,388 | 88,340 | 117,133 | 106,510 | - | - |
| Change | - | -3.22% | 54.13% | 4.68% | 32.59% | -9.07% | - | - |
| Enterprise Value (EV) 1 | 18,842 | 15,118 | 79,713 | 88,340 | 117,133 | 127,766 | 124,239 | 119,252 |
| Change | - | -19.76% | 427.26% | 10.82% | 32.59% | 9.08% | -2.76% | -4.01% |
| P/E ratio | 8.57x | 8.28x | 3.4x | 20x | 20.2x | 13.7x | 10.7x | 9.48x |
| PBR | 0.99x | 1.03x | 1.1x | 1.13x | 1.63x | 1.44x | 1.36x | 1.22x |
| PEG | - | 0.98x | 0x | -0.2x | 0.6x | 0.3x | 0.4x | 0.7x |
| Capitalization / Revenue | 1.72x | 1.72x | 2.37x | 1.99x | 3.05x | 2.61x | 2.54x | 2.45x |
| EV / Revenue | 0.57x | 0.47x | 2.24x | 1.99x | 3.05x | 3.13x | 2.96x | 2.74x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 2.17x | 1.7x | 45.1x | 13.1x | 16.1x | 12x | 9.26x | 8.22x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.4652 | 0.5043 | 0.6101 | 0.8213 | 0.8547 | 0.9734 | 1.072 | 1.161 |
| Rate of return | 2.83% | 2.93% | 2.34% | 2.96% | 2.31% | 2.78% | 3.06% | 3.31% |
| EPS 2 | 1.916 | 2.078 | 7.679 | 1.387 | 1.829 | 2.55 | 3.264 | 3.694 |
| Distribution rate | 24.3% | 24.3% | 7.95% | 59.2% | 46.7% | 38.2% | 32.8% | 31.4% |
| Net sales 1 | 32,928 | 31,923 | 35,591 | 44,359 | 38,428 | 40,759 | 41,930 | 43,525 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | 8,685 | 8,897 | 1,768 | 6,727 | 7,268 | 10,681 | 13,417 | 14,512 |
| Net income 1 | 6,937 | 7,047 | 25,300 | 4,640 | 6,021 | 7,944 | 10,073 | 11,056 |
| Net Debt 1 | -37,735 | -39,634 | -4,675 | - | - | 21,257 | 17,730 | 12,742 |
| Reference price 2 | 16.42 | 17.20 | 26.10 | 27.73 | 36.96 | 35.04 | 35.04 | 35.04 |
| Nbr of stocks (in thousands) | 3,445,569 | 3,182,354 | 3,233,265 | 3,185,707 | 3,169,176 | 3,039,659 | - | - |
| Announcement Date | 01/02/22 | 31/01/23 | 06/02/24 | 04/02/25 | 04/02/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 13.74x | 3.13x | - | 2.78% | 137B | ||
| 22.07x | 5.9x | 12.77x | 2.1% | 168B | ||
| 15.14x | 6.93x | - | 1.67% | 90.94B | ||
| 25.26x | 12.51x | 17.93x | 4.07% | 78.07B | ||
| 10.95x | 1.56x | 4.89x | 1.43% | 41.69B | ||
| 12.46x | 4.88x | - | 2.28% | 41.56B | ||
| 4.23x | 4.1x | 4.44x | 3.23% | 34.95B | ||
| 14.15x | 5x | 15.63x | 2.02% | 29.79B | ||
| 11.78x | 2.43x | 6.17x | 4.95% | 22.44B | ||
| Average | 14.42x | 5.16x | 10.30x | 2.72% | 71.59B | |
| Weighted average by Cap. | 16.67x | 5.65x | 12.02x | 2.55% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- UBSG Stock
- Valuation UBS Group AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















